Imaging3 appoints John Hollister as CEO

BURBANK, Calif., Dec. 20, 2017 -- Imaging3, Inc. (OTCQB:IGNG) announced today that it has appointed John Hollister as chief executive officer and chairman of the board.

Mr. Hollister brings over 25 years of leadership experience in large pharmaceuticals, biotech, and medical device companies.  He has extensive experience in all aspects of commercialization in the healthcare industry, including significant involvement with multiple products successfully undergoing review by the FDA.  Most recently, Mr. Hollister served as CEO of NuLife Sciences, Inc. (OTCQB:NULF) and CEO of NEMUS Bioscience (OTCQB:NMUS).  Prior to NEMUS, he was vice president of marketing for Tethys Bioscience, a diabetes diagnostic company.  Earlier in his career he was the CEO and chairman of EEG Spectrum, an EEG device manufacturer.  John began his career working for SmithKline Beecham and Amgen.

Mr. Hollister earned his B.A. in economics from Stanford University and his MBA from Claremont’s Peter F. Drucker Graduate School of Management.  He serves as a board member for the Brain and Behavior Research Foundation (formerly NARSAD), the world’s leading charity for brain and behavior research.

Mr. Dane Medley, president and principal executive officer stated, “We welcome the addition of John to Imaging3 at this critical time, as we pursue FDA approval via the 510K pathway. In addition, the company will benefit from his experience in raising the capital and building the team necessary to achieve our goals.” 

Mr. Hollister stated, “I am enthused about the opportunity to lead Imaging3 to the key milestone of commercializing an innovative imaging technology that will benefit healthcare providers and their patients alike.  That the Company has reached this point is a credit to our current team of employees and consultants, and to a number of loyal investors as well, who have helped the company emerge from a very difficult few years.  The company can now focus on the last critical steps to carry its innovative technology to market and on enhancing value for our shareholders along the way.”

About Imaging3, Inc.
Imaging3, Inc., founded in 1993, has developed a patented medical imaging technology, called SmartScan™, that will produce 3D x-ray images, virtually in real time. The SmartScan technology will allow healthcare professionals to perform diagnostic and therapeutic procedures more quickly and accurately, resulting in higher throughput for the clinicians and fewer safety risks for the patient. In addition, Imaging3’s technology exposes patients to significantly less harmful radiation than current imaging technologies such as CT scans, which the company believes will allow scans to be used in more pediatric applications than are currently prescribed. The technology also allows for greater portability, easier installation, and a significantly reduced cost burden for the healthcare system overall. Imaging3 is planning to submit a 510K application to the FDA during 2018 in order to gain approval to commercialize the SmartScan technology.

Visit the company’s website at http://www.imaging3.com for detailed information about the company’s technology.

Safe Harbor Statement

Imaging3 cautions you that any statement included in this press release that is not a description of historical facts is a forward-looking statement. Many of these forward-looking statements contain the words "anticipate," "believe," "estimate," "may" "intend," "expect" and similar expressions. Actual results, performance or achievements could differ materially from those contemplated, expressed or implied by the forward-looking statements contained herein. These forward-looking statements are based largely on the expectations of the company and are subject to a number of risks and uncertainties inherent in the Imaging3’s business, including, without limitation: the company may not ever obtain FDA approval for any of its devices; the company may not be able to secure the funds necessary to support its product development plans; and the company may not ever achieve the market success to sustain a profitable business.  In addition, there are risks and uncertainties related to economic recession or terrorist actions, competition from much larger imaging companies, technological obsolescence, unexpected costs and delays, potential product liability claims, and many other factors. More detailed information about Imaging3 and the risk factors that may affect the realization of forward-looking statements is set forth in the company’s filings with the Securities and Exchange Commission, including the company’s Annual Report on Form 10-K and its Quarterly Report on Form 10-Q.  Such documents may be read free of charge on the SEC’s website at www.sec.gov. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and Imaging3 undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.  This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.

Investor Relations Contact:
John Hollister
Chief Executive Officer
[email protected]